Johnson & Johnson is reaffirmed as a buy due to promising pipeline developments and a recent correction in its valuation. The early FDA approval of Icotyde, which has an $8 billion peak sales potential, could contribute approximately 8% annual growth to JNJ's revenue. Analysts expect an EPS compound annual growth rate (CAGR) of 8.9% from 2026 to 2030, while the forward price-to-earnings ratio is projected to decline from 20.8x to 14.8x. A discounted dividend model suggests a fair value of $273 per share, indicating a significant margin of safety at current market prices.
Johnson & Johnson reported strong Q2 sales of $584 million for Spravato, a nasal spray for treatment-resistant depression, signaling robust market potential for psychedelic drugs. Jefferies highlights this growth supports the commercial viability of ...
Johnson & Johnson reported solid Q2 2026 results, achieving 6.6% annual revenue growth driven by strong Pharma and MedTech divisions. The company maintains a portfolio of over 15 blockbuster drugs and a promising pipeline, supporting its status as a ...
Johnson & Johnson reported better-than-expected Q2 2026 results with adjusted EPS of $2.90, surpassing estimates, and revenue of $25.31 billion, driven by strong pharmaceutical sales. Key growth came from the Innovative Medicine segment, with notable...
The FTSE 100 dropped 23 points to 10,506, pressured by mining stocks reacting to China's slower-than-expected 4.3% GDP growth in Q2, its weakest in three years. European markets also declined, while US futures rose, led by tech. PayPal shares surged ...
US stock futures rose after a softer-than-expected Consumer Price Index (CPI) report reduced the chances of a Federal Reserve rate hike in July. The market now awaits today's Producer Price Index (PPI) data, which could either confirm easing inflatio...
